Advertisement

Combination of a Long-Acting β-Agonist and Muscarinic Antagonist Is More Effective Than Either Agent Alone in Advanced COPD

Summary and Comment |
May 15, 2014

Combination of a Long-Acting β-Agonist and Muscarinic Antagonist Is More Effective Than Either Agent Alone in Advanced COPD

  1. David J. Amrol, MD

Combined therapy improved lung function and dyspnea but did not reduce exacerbations in patients with moderate-to-very severe chronic obstructive pulmonary disease.

  1. David J. Amrol, MD

Clinicians have several options for treating patients with stable chronic obstructive pulmonary disease (COPD). The Global Initiative for Chronic Obstructive Lung Disease recommends long-acting bronchodilators for higher-risk patients and those whose symptoms are not controlled with short-acting agents (NEJM JW Gen Med Sep 13 2012). FDA-approved long-acting β-agonists (LABAs) include twice-daily salmeterol (Serevent), formoterol (Foradil), and arformoterol (Brovana), and once-daily indacaterol (Arcapta Neohaler); long-acting muscarinic antagonists (LAMAs) that are approved for treating patients with COPD include twice-daily aclidinium (Tudorza Pressair) and once-daily tiotropium (Spiriva) and umeclidinium (Incruse Ellipta). Addition of inhaled corticosteroids (ICS) is recommended for patients with severe airflow obstruction or continued exacerbations. The combination of a LABA and a LAMA appears to be more efficacious than either agent alone, and some studies suggest that triple therapy with a LABA, a LAMA, and ICS confers even greater benefits.

Combination umeclidinium and vilanterol (a LABA) is FDA-approved for COPD in a once-daily dry powder inhaler (Anoro Ellipta). Researchers examined the long-term efficacy and safety of combination umeclidinium and vilanterol in an industry-sponsored, multicenter trial in which 1500 patients with moderate-to-very severe COPD were randomized to umeclidinium, vilanterol, combination umeclidinium and vilanterol, or placebo for 24 weeks. Half the patients were using inhaled corticosteroids.

Improvements in the primary endpoint of mean change in trough forced expiratory volume in 1 second (FEV1) were significantly greater with combination therapy than with umeclidinium monotherapy and vilanterol monotherapy (0.08 L and 0.11 L, respectively), as were reductions in symptom scores and rescue albuterol use. Risk for exacerbations was lower in all treatment groups compared with placebo, but was no lower with combination therapy than with monotherapy. Adverse events were similar in all groups.

Comment

For patients with chronic obstructive pulmonary disease not controlled with a single, long-acting bronchodilator, treatment with the combination of a long-acting β-agonist and muscarinic antagonist improves lung function and symptoms, although, in this study, it was no better than monotherapy in preventing exacerbations. A reasonable approach when monotherapy fails is to start with either a LABA/LAMA or inhaled corticosteroid/LABA combination, and, if either is ineffective, switch therapies, or try triple therapy with all three. Which LABA/LAMA/ICS combination might be best for high-risk patients or those with uncontrolled COPD is unclear.

  • Disclosures for David J. Amrol, MD at time of publication Consultant / advisory board Dyax Leadership positions in professional societies South Carolina Allergy Society (President)

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement